Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s traded shares stood at 1.25 million during the latest session, with the company’s beta value hitting 0.59. At the last check today, the stock’s price was $15.84, to imply an increase of 1.38% or $0.22 in intraday trading. The TEVA share’s 52-week high remains $22.80, putting it -43.94% down since that peak but still an impressive 21.28% since price per share fell to its 52-week low of $12.47. The company has a valuation of $18.14B, with an average of 10.34 million shares in intraday trading volume over the past 10 days and average of 12.00 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Teva- Pharmaceutical Industries Ltd. ADR (TEVA), translating to a mean rating of 1.73. Of 8 analyst(s) looking at the stock, 1 analyst(s) give TEVA a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 6 recommend it as a Buy.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) trade information
After registering a 1.38% upside in the latest session, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has traded red over the past five days. The 5-day price performance for the stock is 6.49%, and 3.56% over 30 days. With these gigs, the year-to-date price performance is -28.15%. Short interest in Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) saw shorts transact 30.34 million shares and set a 2.56 days time to cover.
The extremes give us $28 and $28 for target low and target high price respectively. As such, TEVA has been trading -76.77% off suggested target high and -76.77% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -9.62% for the past 5-year period. While 2025 is set for a 3.02% return in earnings, projections for the next 5 years are at 6.26% annually.
TEVA Dividends
Teva- Pharmaceutical Industries Ltd. ADR has its next earnings report out on 2025-Jan-28. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. The company’s average dividend yield trailing the past 5-year period is 2.95%.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s Major holders
Teva- Pharmaceutical Industries Ltd. ADR insiders hold 0.00% of total outstanding shares, with institutional holders owning 62.73% of the shares at 62.73% float percentage. In total, 62.73% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 42.99 million shares (or 3.7942% of shares), all amounting to roughly $698.55 million.
The next major institution holding the largest number of shares is FMR LLC with 41.98 million shares, or about 3.7051% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $682.15 million.
We also have Fidelity Contrafund and iShares Trust-iShares Core MSCI EAFE ETF as the top two Mutual Funds with the largest holdings of the Teva- Pharmaceutical Industries Ltd. ADR (TEVA) shares. Going by data provided on Feb 28, 2025 , Fidelity Contrafund holds roughly 18.74 shares. This is just over 1.64% of the total shares, with a market valuation of $297.8 million. Data from the same date shows that the other fund manager holds a little less at 7.16, or 0.62% of the shares, all valued at about 113.82 million.
